Download PDF
Hamostaseologie 2009; 29(04): 381-387
DOI: 10.1055/s-0037-1617129
Review
Schattauer GmbH

Acute coronary syndromes and percutaneous coronary interventions

Impact of bleeding and blood transfusion
J.-P. Bassand
1   Department of Cardiology, University Hospital Jean Minjoz, Besançon, France
› Author Affiliations
Further Information

Publication History

Publication Date:
29 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Activation of the coagulation cascade and platelet functions occurs in ACS and may lead to subsequent thrombus formation, vessel occlusion, distal embolisation, myocardial ischaemia, necrosis and eventually death. Over the last 20 years, the outcome of ACS and PCI patients has considerably improved, thanks to better pharmacologic environment, urgent reperfusion in STEMI (ST elevation myocardial infarction), timely revascularisation in non-ST elevation ACS (NSTEACS) and improved PCI techniques, particularly widespread use of stents.

In this context, bleeding was long considered as inherent to the modern therapeutic approach and without real consequences. Actually, bleeding has a strong impact on outcome, with a four- to five-fold increase in the rate of death, myocardial infarction and stroke at 30 days and six months. In addition, blood transfusion may have deleterious effects. Recent evidence shows that reduced risk of bleeding leads to a reduced risk of ischemic events (death, myocardial infarction and stroke).

The exact mechanisms by which bleeding impacts on outcome are as yet poorly understood. The interruption of active treatment may play an important role. Activation of coagulation or inflammation in case of bleeding, and depletion of 2,3DPG and nitric oxide, inflammatory and immunologic reactions triggered by blood transfusion, are among the potential mechanisms.

Prevention of bleeding has become as important as prevention of ischaemic events. Risk stratification for bleeding is as important as overall risk stratification for further ischaemic events. In patients at high risk of bleeding, appropriate choice and dosage of drugs, combinations of drugs, and the use of radial rather than femoral approach are essential components of bleeding prevention.

Keywords

Acute coronary syndrome - percutaneous coronary intervention
 

  • References

  • 1 Rao SV, Eikelboom JA, Granger CB. et al. Bleeding and blood transfusion issues in patients with nonST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1193-1204.
    CrossrefPubMedGoogle Scholar
  • 2 Eikelboom JW, Mehta SR, Anand SS. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
    CrossrefPubMedGoogle Scholar
  • 3 Rao SV, Jollis JG, Harrington RA. et al. Relationship of blood transfusion and clinical outcomes in patientswith acute coronary syndromes. Jama 2004; 292: 1555-1562.
    CrossrefPubMedGoogle Scholar
  • 4 Rao SV, O’Grady K, Pieper KS. et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-1206.
    CrossrefPubMedGoogle Scholar
  • 5 Bassand JP, Hamm CW, Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
    CrossrefPubMedGoogle Scholar
  • 6 Bassand JP. Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm. Heart 2008; 94: 661-666.
    CrossrefPubMedGoogle Scholar
  • 7 Rao SV, O’Grady K, Pieper KS. et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 809-816.
    CrossrefPubMedGoogle Scholar
  • 8 Moscucci M, Fox KA, Cannon CP. et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-1823.
    CrossrefPubMedGoogle Scholar
  • 9 Doyle BJ, Ting HH, Bell MR. et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17 901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv 2008; 1: 202-209.
    CrossrefPubMedGoogle Scholar
  • 10 Feit F, Voeltz MD, Attubato MJ. et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007; 100: 1364-1369.
    CrossrefPubMedGoogle Scholar
  • 11 Jani SM, Smith DE, Share D. et al. Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention. Clin Cardiol 2007; 30 (10) (Suppl. 02) II49-56.
    PubMedGoogle Scholar
  • 12 Kim P, Dixon S, Eisenbrey AB. et al. Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol 2007; 30 (10) (Suppl. 02) II35-43.
    PubMedGoogle Scholar
  • 13 Kinnaird TD, Stabile E, Mintz GS. et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930-935.
    CrossrefPubMedGoogle Scholar
  • 14 Ndrepepa G, Berger PB, Mehilli J. et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-697.
    CrossrefPubMedGoogle Scholar
  • 15 Fox KA, Dabbous OH, Goldberg RJ. et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). Br Med J 2006; 333: 1091.
    CrossrefPubMedGoogle Scholar
  • 16 Meneveau N, Schiele F, Seronde MF. et al. Anemia for risk assessment of patients with acute coronary syndromes. Am Heart Cardiol 2009; 103: 442-447.
    PubMedGoogle Scholar
  • 17 Voeltz MD, Patel AD, Feit F. et al. Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention. Am J Cardiol 2007; 99: 1513-1517.
    CrossrefPubMedGoogle Scholar
  • 18 Dauerman HL, Lessard D, Yarzebski J. et al. Bleeding complications in patients with anemia and acute myocardial infarction. Am J Cardiol 2005; 96: 1379-1383.
    CrossrefPubMedGoogle Scholar
  • 19 Alexander KP, Chen AY, Roe MT. et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. Jama 2005; 294: 3108-3116.
    CrossrefPubMedGoogle Scholar
  • 20 Granger CB, Goldberg RJ, Dabbous O. et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345-2453.
    CrossrefPubMedGoogle Scholar
  • 21 Eagle KA, Lim MJ, Dabbous OH. et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month post -discharge death in an international registry. Jama 2004; 291: 2727-2733.
    CrossrefPubMedGoogle Scholar
  • 22 Mehta SK, Frutkin AD, Lindsey JB. et al. Bleeding patients undergoing percutaneous coronary intervention: The development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Intervent 2009; 2: 222-229.
    PubMedGoogle Scholar
  • 23 Nikolsky E, Mehran R, Dangas G. et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28: 1936-1945.
    CrossrefPubMedGoogle Scholar
  • 24 Subherwal S, Alexander K. Crusade Bleeding Risk Score. http://www.crusadebleedingscore.org (accessed 2 July 2009).
    PubMedGoogle Scholar
  • 25 Joyner CD, Peters RJ, Afzal R. et al. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. Am Heart J 2009; 157: 502-508.
    CrossrefPubMedGoogle Scholar
  • 26 Budaj A, Eikelboom JW, Mehta SR. et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009; 30: 655-661.
    PubMedGoogle Scholar
  • 27 Spencer FA, Moscucci M, Granger CB. et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. Circulation 2007; 116: 2793-2801.
    CrossrefPubMedGoogle Scholar
  • 28 Manoukian SV, Feit F, Mehran R. et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49: 1362-1368.
    CrossrefPubMedGoogle Scholar
  • 29 Spiess BD. Blood transfusion: the silent epidemic. Ann Thorac Surg 2001; 72: S1832-S1837.
    CrossrefPubMedGoogle Scholar
  • 30 Spiess BD. Blood transfusion for cardiopulmonary bypass: the need to answer a basic question. J Cardio thorac Vasc Anesth 2002; 16: 535-538.
    PubMedGoogle Scholar
  • 31 Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 8: 267-281.
    CrossrefPubMedGoogle Scholar
  • 32 Spiess BD. Risks of transfusion: outcome focus. Transfusion 2004; 44: 4S-14S.
    CrossrefPubMedGoogle Scholar
  • 33 Spiess BD. Choose one: damned if you do/damned if you don’t. Crit Care Med 2005; 33: 1871-1874.
    CrossrefPubMedGoogle Scholar
  • 34 Rawn JD. Blood transfusion in cardiac surgery: a silentepidemic revisited. Circulation 2007; 116: 2523-2524.
    CrossrefPubMedGoogle Scholar
  • 35 Yang X, Alexander KP, Chen AY. et al. The implications of blood transfusions for patients with nonST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005; 46: 1490-1495.
    CrossrefPubMedGoogle Scholar
  • 36 Rao SV, Chiswell K, Sun JL. et al. International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2008; 101: 25-29.
    CrossrefPubMedGoogle Scholar
  • 37 Alexander KP, Chen AY, Wang TY. et al. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J 2008; 155: 1047-1053.
    CrossrefPubMedGoogle Scholar
  • 38 Yatskar L, Selzer F, Feit F. et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardio -vasc Interv 2007; 69: 961-966.
    PubMedGoogle Scholar
  • 39 Chase AJ, Fretz EB, Warburton WP. et al. Association of the arterial access site at angioplasty with transfusion and mortality: the MORTAL study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 2008; 94: 1019-1025.
    CrossrefPubMedGoogle Scholar
  • 40 Murphy GJ, Reeves BC, Rogers CA. et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007; 116: 2544-2552.
    CrossrefPubMedGoogle Scholar
  • 41 Hill SR, Carless PA, Henry DA. et al. Transfusion thresholds and other strategies for guiding allo -geneic red blood cell transfusion. Cochrane Database Syst Rev 2002; CD002042.
    PubMedGoogle Scholar
  • 42 Koch CG, Li L, Sessler DI. et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358: 1229-1239.
    CrossrefPubMedGoogle Scholar
  • 43 Hebert PC, Wells G, Blajchman MA. et al. A multi-center, randomized, controlled clinical trial of transfusion requirements in critical care. Trans-fusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-417.
    CrossrefPubMedGoogle Scholar
  • 44 Hebert PC, Yetisir E, Martin C. et al. Is a low trans-fusion threshold safe in critically ill patients with cardiovascular diseases?. Crit Care Med 2001; 29: 227-234.
    CrossrefPubMedGoogle Scholar
  • 45 Bennett-Guerrero E, Veldman TH, Doctor A. et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci USA 2007; 104: 17063-17068.
    CrossrefPubMedGoogle Scholar
  • 46 Berezina TL, Zaets SB, Morgan C. et al. Influence of storage on red blood cell rheological properties. J Surg Res 2002; 102: 6-12.
    CrossrefPubMedGoogle Scholar
  • 47 Raat NJ, Verhoeven AJ, Mik EG. et al. The effect of storage time of human red cells on intestinal micro-circulatory oxygenation in a rat isovolemic exchange model. Crit Care Med 2005; 33: 39-45 238-239.
    CrossrefPubMedGoogle Scholar
  • 48 Sparrow RL, Veale MF, Healey G. et al. Red blood cell (RBC) age at collection and storage influences RBC membrane-associated carbohydrates and lectin binding. Transfusion 2007; 47: 966-968.
    CrossrefPubMedGoogle Scholar
  • 49 Allen BW, Piantadosi CA. How do red blood cells cause hypoxic vasodilation? The SNO-hemoglobin paradigm. Am J Physiol Heart Circ Physiol 2006; 291: H1507-H1512.
    CrossrefPubMedGoogle Scholar
  • 50 Crawford JH, Isbell TS, Huang Z. et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006; 107: 566-574.
    CrossrefPubMedGoogle Scholar
  • 51 Reynolds JD, Ahearn GS, Angelo M. et al. S-Nitroso -hemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci USA 2007; 104: 17058-17062.
    CrossrefPubMedGoogle Scholar
  • 52 Fransen E, Maessen J, Dentener M. et al. Impact of blood transfusions on inflammatory mediator releasein patients undergoing cardiac surgery. Chest 1999; 116: 1233-1239.
    CrossrefPubMedGoogle Scholar
  • 53 Janatpour K, Holland PV. Noninfectious serious hazards of transfusion. Curr Hematol Rep 2002; 1: 149-155.
    PubMedGoogle Scholar
  • 54 Netzer G, Shah CV, Iwashyna TJ. et al. Association of RBC transfusion with mortality in patients with acute lung injury. Chest 2007; 132: 1116-1123.
    CrossrefPubMedGoogle Scholar
  • 55 Twomley KM, Rao SV, Becker RC. Proinflamma-tory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions. J Thromb Thrombolysis 2006; 21: 167-174.
    CrossrefPubMedGoogle Scholar
  • 56 Vamvakas EC. Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting. Transfus Med Rev 2002; 16: 304-314.
    CrossrefPubMedGoogle Scholar
  • 57 Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2007; 21: 327-348.
    CrossrefPubMedGoogle Scholar
  • 58 Yusuf S, Mehta SR, Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
    CrossrefPubMedGoogle Scholar
  • 59 Stone GW, Witzenbichler B, Guagliumi G. et al. Bivalirudinduring primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
    CrossrefPubMedGoogle Scholar
  • 60 Collet JP, Montalescot G, Agnelli G. et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 2005; 26: 2285-2293.
    CrossrefPubMedGoogle Scholar
  • 61 Agostoni P, Biondi-Zoccai GG, de Benedictis ML. et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 2004; 44: 349-356.
    CrossrefPubMedGoogle Scholar
  • 62 O’Connell KA, Wood JJ, Wise RP. et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. Jama 2006; 295: 293-298.
    CrossrefPubMedGoogle Scholar
  • 63 Samama CM, Djoudi R, Lecompte T. et al. Perioperative platelet transfusion: recommendations of the Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSaPS) 2003. Can J Anaesth 2005; 52: 30-37.
    CrossrefPubMedGoogle Scholar
  • 64 Cannon CP, Husted S, Harrington RA. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
    CrossrefPubMedGoogle Scholar